P

Inventor

DESCHATELETS PASCAL

US33 patents
⚠️ This page may combine multiple inventors who share the name “DESCHATELETS PASCAL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

APELLIS PHARMACEUTICALS INC

19 patents
US10308687B2Jun 4, 2019

Cell-penetrating compstatin analogs and uses thereof

APELLIS PHARMACEUTICALS INC14 citations92
US10035822B2Jul 31, 2018

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

APELLIS PHARMACEUTICALS INC15 citations92
US10875893B2Dec 29, 2020

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

APELLIS PHARMACEUTICALS INC10 citations84
US10407466B2Sep 10, 2019

Methods of selecting compstatin mimetics

APELLIS PHARMACEUTICALS INC12 citations84
US11040107B2Jun 22, 2021

Dosing regimens and related compositions and methods

APELLIS PHARMACEUTICALS INC9 citations83
US11903994B2Feb 20, 2024

Dosing regimens

APELLIS PHARMACEUTICALS INC4 citations73
US11292815B2Apr 5, 2022

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

APELLIS PHARMACEUTICALS INC2 citations73
US11013782B2May 25, 2021

Methods of treating chronic disorders with complement inhibitors

APELLIS PHARMACEUTICALS INC1 citations73
US11001610B2May 11, 2021

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

APELLIS PHARMACEUTICALS INC4 citations73
US12290566B2May 6, 2025

Dosing regimens and related compositions and methods

APELLIS PHARMACEUTICALS INC2 citations72
US11844841B2Dec 19, 2023

Dosing regimens and related compositions and methods

APELLIS PHARMACEUTICALS INC4 citations72
US11407789B2Aug 9, 2022

Cell-penetrating compstatin analogs and uses thereof

APELLIS PHARMACEUTICALS INC2 citations71
US10941184B2Mar 9, 2021

Cell-penetrating compstatin analogs and uses thereof

APELLIS PHARMACEUTICALS INC3 citations71
US11712460B2Aug 1, 2023

Methods of treating chronic disorders with complement inhibitors

APELLIS PHARMACEUTICALS INC0 citations62
US11661441B2May 30, 2023

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

APELLIS PHARMACEUTICALS INC0 citations62
US11291407B2Apr 5, 2022

Detection of high risk drusen

APELLIS PHARMACEUTICALS INC0 citations62
US12528836B2Jan 20, 2026

Dosing regimens

APELLIS PHARMACEUTICALS INC0 citations61
US12458695B2Nov 4, 2025

Dosing regimens and related compositions and methods

APELLIS PHARMACEUTICALS INC0 citations60
US10696718B2Jun 30, 2020

Compstatin analogs for treatment of neuropathic pain

APELLIS PHARMACEUTICALS INC0 citations52

FRANCOIS CEDRIC

5 patents

DESCHATELETS PASCAL

2 patents

POTENTIA PHARMACEUTICALS INC

2 patents

LUNA INNOVATIONS INC

2 patents

ZHANG ZHOUNING

1 patent

HARVARD COLLEGE

1 patent

REVON SYSTEMS LLC

1 patent